“However, we were surprised at how effective the drug worked — almost a miracle drug for this condition.” – Waljit S Dhillo, MBBS, PhD, of Imperial College London, on the ability of an oral NK3R antagonist to improve postmenopausal vasomotor symptoms.
“The key decision point is in the surgeon’s office before surgery.” — Stephen J. Katz, MD, of the University of Michigan in Ann Arbor, commenting on his study showing that fewer than half of breast cancer patients eligible for genetic counseling actually saw a counselor.
“There is this default, that screening must be good — always.” — Otis Brawley, MD, of the American Cancer Society, commenting on a study showing that most men eligible for prostate cancer screening with PSA tests do not have shared decision-making discussions with clinicians.
“Some oncologists are pulling away from anthracyclines and trastuzumab because of this concern of cardiotoxicity … but perhaps we can envision a paradigm where we perform risk-benefit analysis. — Bonnie Ky, MD, of the University of Pennsylvania in Philadelphia, on cardiotoxicity from breast cancer drugs.
“Now we see that we can start with three drugs, and they don’t even have to be that high. Low-dose combinations have synergistic effects that improve blood pressure control.” – Karol Watson, MD, of the David Geffen School of Medicine at the University of California Los Angeles, on a low-dose “triple pill” for hypertension.
“What’s notable about gout is that it keeps bad company — in the form of comorbid illnesses, especially cardiovascular disease.” — Ted R. Mikuls, MD, of the University of Nebraska in Omaha, on the mortality risks associated with gout.
“The protective effect of fat did not make sense.” — Stamatina Iliodromiti, MD, of the University of Glasgow, on her team’s study related to the “obesity paradox.”